Patrick Roth, Thierry Gorlia, Jaap C Reijneveld, Filip de Vos, Ahmed Idbaih, Jean-Sébastien Frenel, Emilie Le Rhun, Juan Manuel Sepulveda, James Perry, G Laura Masucci, Pierre Freres, Hal Hirte, Clemens Seidel, Annemiek Walenkamp, Slavka Lukacova, Paul Meijnders, Andre Blais, Francois Ducray, Vincent Verschaeve, Garth Nicholas, Carmen Balana, Daniela A Bota, Matthias Preusser, Sarah Nuyens, Fréderic Dhermain, Martin van den Bent, Chris J O'Callaghan, Maureen Vanlancker, Warren Mason, Michael Weller
BACKGROUND: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT) and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood brain barrier. METHODS: EORTC 1709/CCTG CE.8 was a multicenter, randomized, controlled, open label phase 3 superiority trial...
March 19, 2024: Neuro-oncology